Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
about
Follicular lymphoma: today's treatments and tomorrow's targets.Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy.Targeted radionuclide therapy.Targeted Therapy in Oncology.The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma.
P2860
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@ast
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@en
type
label
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@ast
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@en
prefLabel
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@ast
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@en
P1433
P1476
Efficacy and safety of 90Y ibr ...... py for non-Hodgkin's lymphoma.
@en
P2093
Thomas E Witzig
P356
10.1053/J.SEMINONCOL.2003.10.007
P433
6 Suppl 17
P577
2003-12-01T00:00:00Z